Table 3.

Treatment-related adverse events^a.

	Rivoceranib N = 80, n (%)
	All grade	Grade 3–4	Grade 5
Hypertension	52 (65.0)	34 (42.5)	0
Fatigue	47 (58.8)	4 (5.0)	0
Nausea	40 (50.0)	2 (2.5)	0
Stomatitis	39 (48.8)	6 (7.5)	0
Proteinuria	31 (38.8)	2 (2.5)	0
Headache	29 (36.3)	0	0
Decreased appetite	29 (36.3)	2 (2.5)	0
Diarrhea	26 (32.5)	1 (1.3)	0
Palmar-plantar erythrodysesthesia syndrome	26 (32.5)	2 (2.5)	0
Aspartate aminotransferase increased	20 (25.0)	2 (2.5)	0
Alanine aminotransferase increased	16 (20.0)	2 (2.5)	0
Oral pain	16 (20.0)	0	0
Vomiting	15 (18.8)	0	0
Weight decreased	15 (18.8)	2 (2.5)	0
Constipation	14 (17.5)	0	0
Platelet count decreased	12 (15.0)	3 (3.8)	0
Rash	11 (13.8)	0	0
Abdominal pain	11 (13.8)	0	0
Gastroesophageal reflux disease	11 (13.8)	0	0
Dysphonia	11 (13.8)	1 (1.3)	0
Blood bilirubin increased	10 (12.5)	0	0
Neutropeniab	9 (11.3)	5 (6.3)	0
Dry mouth	9 (11.3)	0	0
Dyspnea	9 (11.3)	1 (1.3)	0
Dizziness	8 (10.0)	0	0
Epistaxis	7 (8.8)	1 (1.3)	1 (1.3)
Anemia	7 (8.8)	3 (3.8)	0
Back pain	5 (6.3)	1 (1.3)	0
Dermatitis acneiform	4 (5.0)	1 (1.3)	0
Hyponatremia	4 (5.0)	1 (1.3)	0
Dehydration	3 (3.8)	1 (1.3)	0
Embolism	2 (2.5)	1 (1.3)	0
Oral cavity fistula	1 (1.3)	1 (1.3)	0
Posterior reversible encephalopathy syndrome	1 (1.3)	1 (1.3)	0
Seizure	1 (1.3)	1 (1.3)	0
Syncope	1 (1.3)	1 (1.3)	0
Lactic acidosis	1 (1.3)	1 (1.3)	0
Malnutrition	1 (1.3)	1 (1.3)	0
Acute kidney injury	1 (1.3)	1 (1.3)	0
Pleuritic pain	1 (1.3)	1 (1.3)	0
Pneumothorax	1 (1.3)	1 (1.3)	0
Normocytic anemia	1 (1.3)	1 (1.3)	0
Tracheo-esophageal fistula	1 (1.3)	1 (1.3)	0
Cholangitis	1 (1.3)	1 (1.3)	0

^aTreatment-related adverse events of grade 1–2 severity (occurring in ≥10% of patients) and grade 3–5 severity (occurring in any patient).

^bTerm includes neutropenia and decreased neutrophil count.